PARP inhibitor (PARPi) specifically targets HR deficiencies, such as BRCA1 mutations, in tumor cells, and loss of NHEJ renders BRCA1 mutant cells resistant to PARPi (Jackson and Moldovan 2022). This evidence concerns the gene BRCA1 and neoplasm.